<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01898429</url>
  </required_header>
  <id_info>
    <org_study_id>D12051</org_study_id>
    <secondary_id>23293</secondary_id>
    <nct_id>NCT01898429</nct_id>
  </id_info>
  <brief_title>Deep Brain Stimulation (DBS) for Treatment-Resistant Depression (TRD)</brief_title>
  <official_title>Deep Brain Stimulation for Treatment-Resistant Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Paul Holtzheimer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this pilot study, we propose to test whether high frequency stimulation of the subcallosal
      cingulate (SCC) is a safe and efficacious antidepressant treatment in five TRD patients, to
      compare the effects of left-sided vs. right-sided stimulation, and to investigate potential
      mechanisms of action of this intervention. Importantly, this study will be used to assess the
      need for and assist in planning a larger, more definitive trial of SCC DBS for TRD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The U.S. lifetime prevalence of major depressive disorder (MDD) is 17%. A number of
      treatments are available for depression including medications, psychotherapy and various
      somatic treatments. Unfortunately, up to two-thirds of patients remain symptomatic following
      first-line treatment and a third fail to achieve remission (defined as full resolution of
      depressive symptoms) after four established treatments; approximately 10%-20% of depressed
      patients may show virtually no improvement despite multiple, often aggressive treatments.
      Thus, a conservative estimate places the U.S. prevalence of treatment-resistant depression
      (TRD) at 1%-3%. TRD has a high risk of suicide, is a major cause of disability and is
      responsible for doubling of overall health care costs.

      For patients with TRD there are limited evidence-based treatment options. Transcranial
      magnetic stimulation (TMS) may have efficacy for patients that have failed no more than one
      antidepressant medication 10-12, but response and remission rates are relatively low (under
      30% and 20% respectively). Vagus nerve stimulation (VNS) may have efficacy in patients that
      have failed 4-6 antidepressant treatments but long-term response and remission rates are
      again low (about 20% and 10% respectively). Electroconvulsive therapy(ECT) can be effective
      in TRD patients with remission rates of 50%-60%. However, more than 70% of TRD patients will
      relapse within 6 months following a successful acute treatment course. For patients that have
      failed ECT, there are no evidence-based treatment options. Therefore, there is great need for
      novel treatment approaches for TRD.

      Prior clinical trials have shown that SCC DBS has the potential to be a valuable treatment
      option for patients with TRD. Further developing this treatment will involve confirming its
      effectiveness and identifying ways to optimize its use. In this study we intend to test the
      safety and efficacy of chronic SCC DBS as a treatment for TRD and compare the safety and
      efficacy of left-sided versus right-sided stimulation using a double-blind, randomized,
      cross-over design.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of 12 Weeks of Left Unilateral DBS vs. 12 Weeks Right Unilateral DBS on Change in 17-item Hamilton Depression Rating Scale (HDRS-17)</measure>
    <time_frame>baseline, 12 weeks of phase 1, 12 weeks of phase 2 and 12 weeks of phase 3 (bilateral stimulation)</time_frame>
    <description>Baseline HDRS-17 is defined as the average of 4 weekly HDRS-17 in the 4 weeks leading up to surgery. Change in HDRS-17 after 12 weeks of left-sided stimulation (compared to baseline) will be compared to change in HDRS-17 after 12 weeks of right-sided stimulation (compared to baseline). The scale ranges from 0-48 with higher scored indicating more severe depression. A cutoff of 7 or below is considered remission from depression. A decrease of at least 50% from baseline is considered an antidepressant response.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Treatment Resistant Depression</condition>
  <condition>Depressive Disorder, Treatment-Resistant</condition>
  <condition>Depression, Bipolar</condition>
  <arm_group>
    <arm_group_label>Left-sided SCC DBS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active Stimulation of the left-sided electrode</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Right-sided SCC DBS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active stimulation of the right-sided electrode</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SCC DBS</intervention_name>
    <description>Deep Brain Stimulator</description>
    <arm_group_label>Left-sided SCC DBS</arm_group_label>
    <arm_group_label>Right-sided SCC DBS</arm_group_label>
    <other_name>Libra(TM) Implantable Deep Brain Stimulation (DBS) System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        A partial list of eligibility criteria includes:

          -  Age 18-70 years old

          -  Ability to provide written informed consent

          -  Current Major Depressive Episode (MDE), secondary to either Major Depressive Disorder
             or Bipolar Disorder (I, II or NOS)

          -  A current depressive episode of at least 12 months duration

          -  For patients with a bipolar disorder, the last hypomanic or manic episode must have
             been at least 2 years before study entry

          -  A maximum Global Assessment of Functioning of 50

          -  Able to tolerate general anesthesia, DBS surgery and MRI scans

          -  No significant cerebrovascular risk factors or a previous stroke, documented major
             head trauma or neurodegenerative disorder

          -  No currently active clinically significant Axis I psychiatric diagnosis or a
             personality disorder likely to interfere with the study

          -  No evidence of global cognitive impairment

          -  Lives locally or willing to relocate to the area for up to One Year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul E Holtzheimer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 9, 2013</study_first_submitted>
  <study_first_submitted_qc>July 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2013</study_first_posted>
  <results_first_submitted>August 14, 2018</results_first_submitted>
  <results_first_submitted_qc>August 14, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 12, 2018</results_first_posted>
  <last_update_submitted>July 10, 2019</last_update_submitted>
  <last_update_submitted_qc>July 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Dartmouth-Hitchcock Medical Center</investigator_affiliation>
    <investigator_full_name>Paul Holtzheimer</investigator_full_name>
    <investigator_title>Deputy Director for Research at the National Center for PTSD, Associate Professor for Dartmouth/Dartmouth Hitchcock.</investigator_title>
  </responsible_party>
  <keyword>Treatment Resistant Depression</keyword>
  <keyword>Treatment Refractory Depression</keyword>
  <keyword>Treatment Resistant Bipolar Disorder</keyword>
  <keyword>Treatment Refractory Bipolar Disorder</keyword>
  <keyword>Deep brain stimulation</keyword>
  <keyword>DBS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment began in Jan 2012. Participants were enrolled from July 2013 through January 2016. Patients were primarily recruited by clinicaltrials.gov and through information provided to providers.</recruitment_details>
      <pre_assignment_details>All participants entered the left unilateral stimulation phase first; all then transitioned to the right side. This decision was made by the unblinded programmer. Patients and raters were still blinded to treatment allocation.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Left-sided SCC DBS</title>
          <description>Active Stimulation of the left-sided electrode
SCC DBS: Deep Brain Stimulator</description>
        </group>
        <group group_id="P2">
          <title>Right-sided SCC DBS</title>
          <description>Active stimulation of the right-sided electrode
SCC DBS: Deep Brain Stimulator</description>
        </group>
        <group group_id="P3">
          <title>Bilateral SCC DBS</title>
          <description>12 weeks of bilateral SCC DBS</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Phase 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Phase 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All patients entered the left-sided phase first, then crossed over to the right-sided phase.</population>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>Active Stimulation of the left-sided electrode in the first phase (followed by right-sided stimulation in the second phase)
SCC DBS: Deep Brain Stimulator</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hamilton Depression Rating Scale (17 items)</title>
          <description>Standard rating scale for depression severity. Administered by a rater trained and tested for interrater reliability.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.4" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Comparison of 12 Weeks of Left Unilateral DBS vs. 12 Weeks Right Unilateral DBS on Change in 17-item Hamilton Depression Rating Scale (HDRS-17)</title>
        <description>Baseline HDRS-17 is defined as the average of 4 weekly HDRS-17 in the 4 weeks leading up to surgery. Change in HDRS-17 after 12 weeks of left-sided stimulation (compared to baseline) will be compared to change in HDRS-17 after 12 weeks of right-sided stimulation (compared to baseline). The scale ranges from 0-48 with higher scored indicating more severe depression. A cutoff of 7 or below is considered remission from depression. A decrease of at least 50% from baseline is considered an antidepressant response.</description>
        <time_frame>baseline, 12 weeks of phase 1, 12 weeks of phase 2 and 12 weeks of phase 3 (bilateral stimulation)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Stimulation of the left-sided electrode in the first phase (followed by right-sided stimulation in the second phase)
SCC DBS: Deep Brain Stimulator</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of 12 Weeks of Left Unilateral DBS vs. 12 Weeks Right Unilateral DBS on Change in 17-item Hamilton Depression Rating Scale (HDRS-17)</title>
          <description>Baseline HDRS-17 is defined as the average of 4 weekly HDRS-17 in the 4 weeks leading up to surgery. Change in HDRS-17 after 12 weeks of left-sided stimulation (compared to baseline) will be compared to change in HDRS-17 after 12 weeks of right-sided stimulation (compared to baseline). The scale ranges from 0-48 with higher scored indicating more severe depression. A cutoff of 7 or below is considered remission from depression. A decrease of at least 50% from baseline is considered an antidepressant response.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.35" lower_limit="20.25" upper_limit="25.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks left-sided stimulation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8" lower_limit="16" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks right-sided stimulation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4" lower_limit="18" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks of bilateral stimulation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" lower_limit="6" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>40 weeks following surgery to implant the DBS device</time_frame>
      <desc>adverse events data were collected using the SAFTEE developed by the NIH</desc>
      <group_list>
        <group group_id="E1">
          <title>All Participants</title>
          <description>Active Stimulation of the left-sided electrode in the first phase (followed by right-sided stimulation in the second phase)
SCC DBS: Deep Brain Stimulator</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>altered mental status</sub_title>
                <description>confusion related to oxycodone use post-surgery leading to emergency room visit (no hospitalization required)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>multiple</sub_title>
                <description>Multiple mild adverse events were identified using the SAFTEE. Only 1 of 38 (pain at the IPG implantation site) was deemed to be related to the surgery or study device.</description>
                <counts group_id="E1" events="38" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Paul E. Holtzheimer, MD</name_or_title>
      <organization>Dartmouth Hitchcock Medical Center</organization>
      <phone>603-650-4914</phone>
      <email>Paul.E.Holtzheimer@hitchcock.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

